Richard Lent

1.1k total citations
22 papers, 720 citations indexed

About

Richard Lent is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Richard Lent has authored 22 papers receiving a total of 720 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Hematology and 4 papers in Oncology. Recurrent topics in Richard Lent's work include Multiple Myeloma Research and Treatments (6 papers), Cancer Treatment and Pharmacology (4 papers) and Cancer therapeutics and mechanisms (3 papers). Richard Lent is often cited by papers focused on Multiple Myeloma Research and Treatments (6 papers), Cancer Treatment and Pharmacology (4 papers) and Cancer therapeutics and mechanisms (3 papers). Richard Lent collaborates with scholars based in United States and Netherlands. Richard Lent's co-authors include Carl Franzblau, Paul Szabo, Linda H. Younkin, Richard I. Schiff, Norman Relkin, Steven G. Younkin, Marc E. Weksler, Barbara Faris, Lily L. Salcedo and Barbara D. Smith and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Biochemistry.

In The Last Decade

Richard Lent

22 papers receiving 668 citations

Peers

Countries citing papers authored by Richard Lent

Since Specialization

Citations

This map shows the geographic impact of Richard Lent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Lent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Lent more than expected).

Fields of papers citing papers by Richard Lent

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Lent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Lent. The network helps show where Richard Lent may publish in the future.

Co-authorship network of co-authors of Richard Lent

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Lent. A scholar is included among the top collaborators of Richard Lent based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Lent. Richard Lent is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma 2008 ·British Journal of Haematology ·Tomer M. Mark, David Jayabalan, Morton Coleman, Roger Pearse, Y. Lynn Wang, Richard Lent, Paul J. Christos, Joong W. Lee, Yash Pal Agrawal, Susan Matthew, Scott Ely, Madhu Mazumdar, Ethel Cesarman, John P. Leonard, Richard R. Furman, Selina Chen‐Kiang, Rubén Niesvizky	33
2	18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease 2008 ·Neurobiology of Aging ·Norman Relkin, Paul Szabo, (unknown), (unknown), (unknown), Richard Lent, Steven G. Younkin, Linda H. Younkin, Richard I. Schiff, Marc E. Weksler	259
3	Lenalidomide‐induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment‐naïve patients undergoing front‐line lenalidomide and dexamethasone therapy 2007 ·British Journal of Haematology ·Rubén Niesvizky, Tara Naib, Paul J. Christos, David Jayabalan, Jessica Furst, Jessica Jalbrzikowski, Faiza Zafar, Tomer M. Mark, Richard Lent, Roger Pearse, Scott Ely, John P. Leonard, Madhu Mazumdar, Selina Chen‐Kiang, Morton Coleman	68
4	Atypical Serum Immunofixation Pattern (ASIP) Development during Induction Therapy with BiRD for Newly Diagnosed Multiple Myeloma Correlates with a High Rate of Complete Remission. 2007 ·Blood ·Tomer M. Mark, David Jayabalan, Roger Pearse, Y. Lynn Wang, Richard Lent, Paul J. Christos, Joong W. Lee, (unknown), Susan Matthews, Scott Ely, Madhu Mazumdar, Ethel Cesarman, (unknown), John P. Leonard, Morton Coleman, Selina Chen‐Kiang, Rubén Niesvizky	1
5	Clarithromycin, lenalidomide and dexamethasone combination therapy as primary treatment of multiple myeloma 2006 ·Journal of Clinical Oncology ·Rubén Niesvizky, David Jayabalan, Jessica Furst, (unknown), Roger Pearse, Faiza Zafar, Richard Lent, (unknown), Michael W. Schuster, John P. Leonard, Morton Coleman	5
6	BiRD (Biaxin®/Revlimid®/Dexamethasone) Combination Therapy (Rx) Results in High Complete Remissions (CR) and Overall Responses in Myeloma (MM) with Poor Prognostic Features. 2005 ·Blood ·Rubén Niesvizky, Karen Pekle, (unknown), Faiza Zafar, S. Ostrow, Roger Pearse, (unknown), (unknown), Scott Ely, Richard Lent, David Jayabalan, Tsiporah B. Shore, John G. Harpel, Michael Schuster, (unknown), Richard R. Furman, John P. Leonard, Selina Chen‐Kiang, Morton Coleman	3
7	Gadodiamide Administration Causes Spurious Hypocalcemia 2003 ·Radiology ·Martin R. Prince, (unknown), Richard Lent, Jon D. Blumenfeld, K. Craig Kent, Harry L. Bush, Yi Wang	59
8	Serum cardiac troponin I in acute rheumatic fever 2002 ·The American Journal of Cardiology ·Monesha Gupta‐Malhotra, Richard Lent, Edward L. Kaplan, John B. Zabriskie	28
9	No Evidence of Cardiac Troponin I in Acute Rheumatic-Fever 1999 ·Pediatric Research ·Monesha Gupta‐Malhotra, Richard Lent, John B. Zabriskie	1
10	Troponin I as a Marker for Myocardial Injury and Ischemia during Pediatric Cardiopulmonary Bypass Surgery 1999 ·Pediatric Research ·Monesha Gupta‐Malhotra, Richard Lent, Jeffrey H. Kern, Patrick Flynn, Arthur A. Klein, (unknown), Deborah Friedman	1
11	From data to information: how to define the context? 1995 ·Chemometrics and Intelligent Laboratory Systems ·(unknown), Richard Lent	5
12	Quality Improvement Practices in Clinical and Anatomic Pathology Services:A College of American Pathologists Q-Probes Study of the Program Characteristics and Performance in 580 Institutions 1994 ·American Journal of Clinical Pathology ·Paul Bachner, (unknown), Richard Lent	13
13	Intervention time series analysis — sampling strategies 1990 ·Chemometrics and Intelligent Laboratory Systems ·(unknown), (unknown), (unknown), Richard Lent	2
14	Chemical Debridement of Burns 1981 ·The Journal of Trauma: Injury, Infection, and Critical Care ·Stanley Μ. Levenson, (unknown), (unknown), Richard Lent, Eli Seifter	13
15	A model for applying cost-effectiveness analysis to decisions involving the use of instructional technology 1979 ·Journal of Instructional Development ·Richard Lent	5
16	Chemical Debridement of Burns 1974 ·Annals of Surgery ·Stanley Μ. Levenson, (unknown), (unknown), L. V. Crowley, Richard Lent, (unknown), Eli Seifter	16
17	The nature of the intramolecular cross-link in collagen 1969 ·Biochemical and Biophysical Research Communications ·Marcos Rojkind, A.M. Gutiérrez, (unknown), Richard Lent	19
18	Aldehydes in native and denatured calf skin tropocollagen 1969 ·Biochemical and Biophysical Research Communications ·M. A. Paz, Richard Lent, Barbara Faris, Carl Franzblau, Olga O. Blumenfeld, Paul M. Gallop	32
19	Reduction of elastin. II. Evidence for the presence of α-aminoadipic acid .delta.-semialdehyde and its aldol condensation product 1969 ·Biochemistry ·Richard Lent, Barbara D. Smith, Lily L. Salcedo, Barbara Faris, Carl Franzblau	97
20	Studies on the reduction of bovine elastin: Evidence for the presence of Δ6,7-dehydrolysinonorleucine 1967 ·Biochemical and Biophysical Research Communications ·Richard Lent, Carl Franzblau	52

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact